{"transactions":[{"id":4624659,"issuer":{"id":6185,"kind":"organization","name":"Atrium Therapeutics, Inc.","symbol":"RNA"},"owners":[{"id":51570,"kind":"person","name":"Younis Husam","position":1,"cik":"0002107586","reported_name":"Younis Husam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-09-22T20:24:41.000Z","date":"2026-09-18","kind":"tax_withholding","planned":false,"acquired":false,"shares":11216,"price":8.95,"value":100383.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":41441,"source":{"system":"sec-edgar","filing":"0001193125-26-397971","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2107586/000119312526397971/ownership.xml","form_type":"4"}},{"id":4624657,"issuer":{"id":6185,"kind":"organization","name":"Atrium Therapeutics, Inc.","symbol":"RNA"},"owners":[{"id":51597,"kind":"person","name":"Hughes Steven George","position":1,"cik":"0001747528","reported_name":"Hughes Steven George","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-09-22T20:23:56.000Z","date":"2026-09-18","kind":"tax_withholding","planned":false,"acquired":false,"shares":21459,"price":8.95,"value":192058.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":51638,"source":{"system":"sec-edgar","filing":"0001193125-26-397967","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2093101/000119312526397967/ownership.xml","form_type":"4"}},{"id":4624654,"issuer":{"id":6185,"kind":"organization","name":"Atrium Therapeutics, Inc.","symbol":"RNA"},"owners":[{"id":63865,"kind":"person","name":"Flanagan W. Michael","position":1,"cik":"0001841990","reported_name":"Flanagan W. Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-22T20:20:33.000Z","date":"2026-09-18","kind":"tax_withholding","planned":false,"acquired":false,"shares":22812,"price":8.95,"value":204167.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":31974,"source":{"system":"sec-edgar","filing":"0001193125-26-397955","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2093101/000119312526397955/ownership.xml","form_type":"4"}},{"id":4624650,"issuer":{"id":6185,"kind":"organization","name":"Atrium Therapeutics, Inc.","symbol":"RNA"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-22T20:20:02.000Z","date":"2026-09-18","kind":"tax_withholding","planned":false,"acquired":false,"shares":126418,"price":8.95,"value":1131441.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":138668,"source":{"system":"sec-edgar","filing":"0001193125-26-397951","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2093101/000119312526397951/ownership.xml","form_type":"4"}},{"id":4624642,"issuer":{"id":6185,"kind":"organization","name":"Atrium Therapeutics, Inc.","symbol":"RNA"},"owners":[{"id":51573,"kind":"person","name":"Kenney Stephanie","position":1,"cik":"0002105422","reported_name":"Kenney Stephanie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-22T20:18:49.000Z","date":"2026-09-18","kind":"tax_withholding","planned":false,"acquired":false,"shares":2375,"price":8.95,"value":21256.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":33085,"source":{"system":"sec-edgar","filing":"0001193125-26-397948","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2105422/000119312526397948/ownership.xml","form_type":"4"}},{"id":4624627,"issuer":{"id":6185,"kind":"organization","name":"Atrium Therapeutics, Inc.","symbol":"RNA"},"owners":[{"id":51578,"kind":"person","name":"Gallagher Kathleen P.","position":1,"cik":"0002048409","reported_name":"Gallagher Kathleen P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-22T20:17:39.000Z","date":"2026-09-18","kind":"tax_withholding","planned":false,"acquired":false,"shares":11632,"price":8.95,"value":104106.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":119729,"source":{"system":"sec-edgar","filing":"0001193125-26-397944","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2093101/000119312526397944/ownership.xml","form_type":"4"}},{"id":4624620,"issuer":{"id":6185,"kind":"organization","name":"Atrium Therapeutics, Inc.","symbol":"RNA"},"owners":[{"id":51572,"kind":"person","name":"Winslow Brendan R.","position":1,"cik":"0002105552","reported_name":"Winslow Brendan R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-22T20:17:10.000Z","date":"2026-09-18","kind":"tax_withholding","planned":false,"acquired":false,"shares":6742,"price":8.95,"value":60340.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":36859,"source":{"system":"sec-edgar","filing":"0001193125-26-397941","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2105552/000119312526397941/ownership.xml","form_type":"4"}},{"id":4624601,"issuer":{"id":6185,"kind":"organization","name":"Atrium Therapeutics, Inc.","symbol":"RNA"},"owners":[{"id":51571,"kind":"person","name":"Hoyos Rocio Martin","position":1,"cik":"0002107515","reported_name":"Hoyos Rocio Martin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2026-09-22T20:15:53.000Z","date":"2026-09-18","kind":"tax_withholding","planned":false,"acquired":false,"shares":8320,"price":8.95,"value":74464.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":38340,"source":{"system":"sec-edgar","filing":"0001193125-26-397936","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2107515/000119312526397936/ownership.xml","form_type":"4"}},{"id":802333,"issuer":{"id":6185,"kind":"organization","name":"Atrium Therapeutics, Inc.","symbol":"RNA"},"owners":[{"id":51573,"kind":"person","name":"Kenney Stephanie","position":1,"cik":"0002105422","reported_name":"Kenney Stephanie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-22T21:54:12.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent (25%) of the shares underlying this option shall vest and become exercisable on March 20, 2027, with the remaining shares vesting in thirty-six (36) substantially equal monthly installments each month thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":60000,"derivative":{"exercise_price":14.3,"expiration_date":"2036-04-20","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001193125-26-170964","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2093101/000119312526170964/ownership.xml","form_type":"4"}},{"id":802332,"issuer":{"id":6185,"kind":"organization","name":"Atrium Therapeutics, Inc.","symbol":"RNA"},"owners":[{"id":51573,"kind":"person","name":"Kenney Stephanie","position":1,"cik":"0002105422","reported_name":"Kenney Stephanie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-04-22T21:54:12.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Twenty-five percent (25%) of the RSUs shall vest on March 20, 2027, with the remaining RSUs vesting in three (3) substantially equal yearly installments each year thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":35460,"source":{"system":"sec-edgar","filing":"0001193125-26-170964","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2093101/000119312526170964/ownership.xml","form_type":"4"}},{"id":802331,"issuer":{"id":6185,"kind":"organization","name":"Atrium Therapeutics, Inc.","symbol":"RNA"},"owners":[{"id":51572,"kind":"person","name":"Winslow Brendan R.","position":1,"cik":"0002105552","reported_name":"Winslow Brendan R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-22T21:53:36.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent (25%) of the shares underlying this option shall vest and become exercisable on March 20, 2027, with the remaining shares vesting in thirty-six (36) substantially equal monthly installments each month thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":60000,"derivative":{"exercise_price":14.3,"expiration_date":"2036-04-20","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001193125-26-170960","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2093101/000119312526170960/ownership.xml","form_type":"4"}},{"id":802330,"issuer":{"id":6185,"kind":"organization","name":"Atrium Therapeutics, Inc.","symbol":"RNA"},"owners":[{"id":51572,"kind":"person","name":"Winslow Brendan R.","position":1,"cik":"0002105552","reported_name":"Winslow Brendan R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-04-22T21:53:36.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Twenty-five percent (25%) of the RSUs shall vest on March 20, 2027, with the remaining RSUs vesting in three (3) substantially equal yearly installments each year thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":43601,"source":{"system":"sec-edgar","filing":"0001193125-26-170960","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2093101/000119312526170960/ownership.xml","form_type":"4"}},{"id":802329,"issuer":{"id":6185,"kind":"organization","name":"Atrium Therapeutics, Inc.","symbol":"RNA"},"owners":[{"id":51571,"kind":"person","name":"Hoyos Rocio Martin","position":1,"cik":"0002107515","reported_name":"Hoyos Rocio Martin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Strategy Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-22T21:41:09.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent (25%) of the shares underlying this option shall vest and become exercisable on March 20, 2027, with the remaining shares vesting in thirty-six (36) substantially equal monthly installments each month thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":60000,"derivative":{"exercise_price":14.3,"expiration_date":"2036-04-20","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001193125-26-170907","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2093101/000119312526170907/ownership.xml","form_type":"4"}},{"id":802328,"issuer":{"id":6185,"kind":"organization","name":"Atrium Therapeutics, Inc.","symbol":"RNA"},"owners":[{"id":51571,"kind":"person","name":"Hoyos Rocio Martin","position":1,"cik":"0002107515","reported_name":"Hoyos Rocio Martin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2026-04-22T21:41:09.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Twenty-five percent (25%) of the RSUs shall vest on March 20, 2027, with the remaining RSUs vesting in three (3) substantially equal yearly installments each year thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":46660,"source":{"system":"sec-edgar","filing":"0001193125-26-170907","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2093101/000119312526170907/ownership.xml","form_type":"4"}},{"id":802327,"issuer":{"id":6185,"kind":"organization","name":"Atrium Therapeutics, Inc.","symbol":"RNA"},"owners":[{"id":51570,"kind":"person","name":"Younis Husam","position":1,"cik":"0002107586","reported_name":"Younis Husam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-22T21:40:29.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent (25%) of the shares underlying this option shall vest and become exercisable on March 20, 2027, with the remaining shares vesting in thirty-six (36) substantially equal monthly installments each month thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":60000,"derivative":{"exercise_price":14.3,"expiration_date":"2036-04-20","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001193125-26-170906","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2093101/000119312526170906/ownership.xml","form_type":"4"}},{"id":802326,"issuer":{"id":6185,"kind":"organization","name":"Atrium Therapeutics, Inc.","symbol":"RNA"},"owners":[{"id":51570,"kind":"person","name":"Younis Husam","position":1,"cik":"0002107586","reported_name":"Younis Husam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-04-22T21:40:29.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Twenty-five percent (25%) of the RSUs shall vest on March 20, 2027, with the remaining RSUs vesting in three (3) substantially equal yearly installments each year thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":52657,"source":{"system":"sec-edgar","filing":"0001193125-26-170906","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2093101/000119312526170906/ownership.xml","form_type":"4"}},{"id":802493,"issuer":{"id":6185,"kind":"organization","name":"Atrium Therapeutics, Inc.","symbol":"RNA"},"owners":[{"id":51597,"kind":"person","name":"Hughes Steven George","position":1,"cik":"0001747528","reported_name":"Hughes Steven George","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-22T17:54:06.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent (25%) of the shares underlying this option shall vest and become exercisable on March 20, 2027, with the remaining shares vesting in thirty-six (36) substantially equal monthly installments each month thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":60000,"derivative":{"exercise_price":14.3,"expiration_date":"2036-04-20","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001193125-26-170963","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1747528/000119312526170963/ownership.xml","form_type":"4"}},{"id":802492,"issuer":{"id":6185,"kind":"organization","name":"Atrium Therapeutics, Inc.","symbol":"RNA"},"owners":[{"id":51597,"kind":"person","name":"Hughes Steven George","position":1,"cik":"0001747528","reported_name":"Hughes Steven George","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-04-22T17:54:06.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Twenty-five percent (25%) of the RSUs shall vest on March 20, 2027, with the remaining RSUs vesting in three (3) substantially equal yearly installments each year thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":73097,"source":{"system":"sec-edgar","filing":"0001193125-26-170963","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1747528/000119312526170963/ownership.xml","form_type":"4"}},{"id":802339,"issuer":{"id":6185,"kind":"organization","name":"Atrium Therapeutics, Inc.","symbol":"RNA"},"owners":[{"id":51578,"kind":"person","name":"Gallagher Kathleen P.","position":1,"cik":"0002048409","reported_name":"Gallagher Kathleen P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-22T17:43:12.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":205000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent (25%) of the shares underlying this option shall vest and become exercisable on March 20, 2027, with the remaining shares vesting in thirty-six (36) substantially equal monthly installments each month thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":205000,"derivative":{"exercise_price":14.3,"expiration_date":"2036-04-20","underlying":"Common Stock","underlying_shares":205000},"source":{"system":"sec-edgar","filing":"0001193125-26-170914","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2048409/000119312526170914/ownership.xml","form_type":"4"}},{"id":802338,"issuer":{"id":6185,"kind":"organization","name":"Atrium Therapeutics, Inc.","symbol":"RNA"},"owners":[{"id":51578,"kind":"person","name":"Gallagher Kathleen P.","position":1,"cik":"0002048409","reported_name":"Gallagher Kathleen P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-04-22T17:43:12.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":102500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Twenty-five percent (25%) of the RSUs shall vest on March 20, 2027, with the remaining RSUs vesting in three (3) substantially equal yearly installments each year thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":131361,"source":{"system":"sec-edgar","filing":"0001193125-26-170914","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2048409/000119312526170914/ownership.xml","form_type":"4"}},{"id":874052,"issuer":{"id":6185,"kind":"organization","name":"Atrium Therapeutics, Inc.","symbol":"RNA"},"owners":[{"id":35186,"kind":"person","name":"Boyce Sarah","position":1,"cik":"0001629383","reported_name":"Boyce Sarah","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-02T23:00:08.000Z","date":"2026-02-27","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on February 27, 2026 and the shares underlying the options vest in equal monthly installments over the three years following the grant date, subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":20000,"derivative":{"exercise_price":14.75,"expiration_date":"2036-02-27","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001193125-26-085922","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629383/000119312526085922/ownership.xml","form_type":"4"}},{"id":873714,"issuer":{"id":6185,"kind":"organization","name":"Atrium Therapeutics, Inc.","symbol":"RNA"},"owners":[{"id":32079,"kind":"person","name":"BOESS CARSTEN","position":1,"cik":"0001277495","reported_name":"BOESS CARSTEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-02T23:00:07.000Z","date":"2026-02-27","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on February 27, 2026 and the shares underlying the options vest in equal monthly installments over the three years following the grant date, subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":20000,"derivative":{"exercise_price":14.75,"expiration_date":"2036-02-27","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001193125-26-085921","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1277495/000119312526085921/ownership.xml","form_type":"4"}},{"id":873524,"issuer":{"id":6185,"kind":"organization","name":"Atrium Therapeutics, Inc.","symbol":"RNA"},"owners":[{"id":20321,"kind":"person","name":"WILSON TROY EDWARD","position":1,"cik":"0001589597","reported_name":"WILSON TROY EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-02T23:00:05.000Z","date":"2026-02-27","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on February 27, 2026 and the shares underlying the options vest in equal monthly installments over the three years following the grant date, subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":20000,"derivative":{"exercise_price":14.75,"expiration_date":"2036-02-27","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001193125-26-085920","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1589597/000119312526085920/ownership.xml","form_type":"4"}},{"id":874722,"issuer":{"id":6185,"kind":"organization","name":"Atrium Therapeutics, Inc.","symbol":"RNA"},"owners":[{"id":31759,"kind":"person","name":"Skerjanec Simona","position":1,"cik":"0002022163","reported_name":"Skerjanec Simona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-02T23:00:02.000Z","date":"2026-02-27","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on February 27, 2026 and the shares underlying the options vest in equal monthly installments over the three years following the grant date, subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":20000,"derivative":{"exercise_price":14.75,"expiration_date":"2036-02-27","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001193125-26-085918","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022163/000119312526085918/ownership.xml","form_type":"4"}},{"id":873335,"issuer":{"id":6185,"kind":"organization","name":"Atrium Therapeutics, Inc.","symbol":"RNA"},"owners":[{"id":63865,"kind":"person","name":"Flanagan W. Michael","position":1,"cik":"0001841990","reported_name":"Flanagan W. Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-02T18:00:04.000Z","date":"2026-02-27","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on February 27, 2026 and the shares underlying the options vest in equal monthly installments over the three years following the grant date, subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":20000,"derivative":{"exercise_price":14.75,"expiration_date":"2036-02-27","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001193125-26-085919","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841990/000119312526085919/ownership.xml","form_type":"4"}}]}